Stockscreener 앱 받기
0.2687
4.68%
-0.0133
전일 마감가:
$0.282
열려 있는:
$0.2821
하루 거래량:
429.21K
Relative Volume:
0.85
시가총액:
$22.49M
수익:
-
순이익/손실:
$-16.63M
주가수익비율:
-0.4554
EPS:
-0.59
순현금흐름:
$-21.84M
1주 성능:
-2.96%
1개월 성능:
-21.06%
6개월 성능:
-19.26%
1년 성능:
-72.12%
1일 변동 폭
$0.262
$0.303
1주일 범위:
$0.262
$0.303
52주 변동 폭
$0.134
$1.08
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
명칭
Brainstorm Cell Therapeutics Inc
전화
201-488-0460
주소
1325 AVENUE OF AMERICAS, NEW YORK, NY
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-02-04 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-11-17 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2016-12-19 | 재확인 | Maxim Group | Buy |
| 2015-12-22 | 재확인 | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc 주식(BCLI)의 최신 뉴스
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Receives New Coverage from Analysts at StockNews.com - Defense World
Global Stem Cell Therapy Market Technology, Dimension, Vertical, and Regional Insights 2024-2032 - 대구포스트
Gene and Cell Therapies Targeting CNS Disorders Market Growth - openPR
5 Best Stem Cell Companies to Invest In (September 2024) - Securities.io
SEC Form S-3 filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Zacks Small Cap Analysts Reduce Earnings Estimates for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Announces Earnings Results, Hits Expectations - Defense World
Thinking about buying stock in Brainstorm Cell Therapeutics, Cle - GuruFocus.com
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2024 Earnings Call Transcript - Insider Monkey
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Longview News-Journal
Earnings call: Brainstorm Cell Therapeutics outlines Phase 3b trial plans By Investing.com - Investing.com Canada
Earnings call: Brainstorm Cell Therapeutics outlines Phase 3b trial plans - Investing.com
Earnings call: Brainstorm Cell Therapeutics outlines Phase 3b trial plans By Investing.com - Investing.com India
Earnings call: Brainstorm Cell Therapeutics outlines Phase 3b trial plans By Investing.com - Investing.com UK
BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - citybiz
BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Indo-Asian News Service - IANS India Pvt Ltd
Brainstorm Cell Therapeutics, Inc.: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - The InvestChronicle
Ratios Reveal: Breaking Down Brainstorm Cell Therapeutics, Inc. (BCLI)’s Financial Health - The Dwinnex
Brainstorm Cell Therapeutics (BCLI) to Release Earnings on Wednesday - Defense World
Cell Theraputics Market Global and Regional Analysis - Economica
Brainstorm Cell Therapeutics, Inc. [BCLI] stock was sold by Dagher Ibrahim B. at the price of US$22069.0 - Knox Daily
BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update - The Malaysian Reserve
BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update - StockTitan
Financial Analysis: Vaxcyte (NASDAQ:PCVX) vs. Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - Defense World
BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration - Quantisnow
BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate Update - Quantisnow
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn® - Quantisnow
BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia - Quantisnow
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum - Quantisnow
Reviewing IN8bio (NASDAQ:INAB) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Ratios in Focus: Analyzing Brainstorm Cell Therapeutics, Inc. (BCLI)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Amyotrophic Lateral Sclerosis Clinical Trials | A Drug Pipeline - openPR
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com - Defense World
BCLI overperforms with a 2.66 increase in share price - US Post News
Brainstorm cell therapeutics CMO sells $22,068 in stock - Investing.com India
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Insider Ibrahim B. Dagher Sells 63,000 Shares - Defense World
Brainstorm cell therapeutics CMO sells $22,068 in stock - Investing.com
Brainstorm cell therapeutics CMO sells $22,068 in stock By Investing.com - Investing.com Nigeria
BCLI UpdateProgress Supports Our 10x Plus Value Range Potential - Quantisnow
Amyotrophic Lateral Sclerosis Treatment Market size is set to grow by USD 663.7 million from 2024-2028, Increase in incidence and prevalence of amyotrophic lateral sclerosis to boost the market growth, Technavio - The Malaysian Reserve
BrainStorm Cell Therapeutics (BCLI) Update 23072024 - Smartkarma
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com - American Banking and Market News
BrainStorm Gears Up for Phase IIIb NurOwn Trial Amidst ALS Malaise - BioSpace
BrainStorm faces delisting over market value shortfall By Investing.com - Investing.com Australia
BrainStorm faces delisting over market value shortfall - Investing.com
Autologous Stem Cell and Non-Stem Cell Based Therapies Market - openPR
Around the Helix: Cell and Gene Therapy Company Updates – July 17, 2024 - CGTLive™
Brainstorm Cell Therapeutics, Inc. (BCLI) stock analysis: A simple moving average approach - US Post News
Brainstorm Cell Therapeutics Inc (BCLI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.19%
1.76%
자본화:
|
볼륨(24시간):